IMAX Corporation filings document the formal records behind its entertainment-technology business, NYSE-listed common shares and reported operating results. Recent Form 8-K disclosures cover quarterly and annual financial results, global box office metrics, system installations and signings, material agreements and financing activity, including convertible senior notes.
Proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. Other current reports address leadership-continuity and governance disclosures, while filings also identify the company as a Canadian corporation with operations reported through Content Solutions and Technology Products and Services.
IMAX: Macquarie entities filed Amendment No. 2 to Schedule 13G reporting beneficial ownership of 4,612,983 common shares, representing 8.58% of the class as of 09/30/2025.
Macquarie Management Holdings Inc. and Macquarie Investment Management Business Trust each report sole voting and sole dispositive power over 4,612,983 shares. Macquarie Group Limited reports an aggregate beneficial amount of 4,612,983 shares with zero sole or shared voting/dispositive power on its cover page.
The filing includes a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
IMAX Corp reported a Form 4 for CEO and Director Richard L. Gelfond, who gifted 40,000 common shares on 11/10/2025 (transaction code G) to a donor‑advised fund for charitable purposes. After the transfer, he beneficially owns 564,599 common shares directly.
The filing also lists his outstanding awards following the transaction: 1,818,695 options and 294,433 restricted share units. It states the timing relates to changes in tax regulations taking effect on 01/01/2026.
IMAX (IMAX) executive Mark Welton reported an option exercise and share sale. On 11/10/2025, he exercised stock options into 49,504 common shares at $22.49 per share and sold 49,504 common shares at a price of $35.228.
Following these transactions, he beneficially owns 153,323 common shares directly. The filing notes 70,609 restricted share units outstanding after these transactions and that the options exercised were issued in 2019 and set to expire on March 7, 2026.
IMAX Chief Commercial Officer Giovanni M. Dolci reported an option exercise and same‑day sale. On 11/10/2025, he exercised 6,188 stock options at $22.49 and sold 6,188 common shares at a weighted average price of $34.2452, leaving 33,000 common shares held directly.
The options were issued in 2019 and are set to expire on March 7, 2026. The filing notes remaining restricted share units of 21,574 following these transactions.
IMAX (IMAX) reported an insider transaction by CTO & EVP Pablo Calamera. On 11/10/2025, he executed a sale coded “S” of 20,586 common shares at a price of $34.2255 per share. Following the sale, his beneficially owned common shares total 40,886, held directly.
The filing also notes remaining restricted share units of 32,863 after the reported transactions. This Form 4 reflects a routine insider share sale and updated holdings.
IMAX filed a Form 144 indicating a proposed sale of 20,586 common shares through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $704,566.14 and an approximate sale date of 11/10/2025.
The shares to be sold were acquired via restricted stock vesting under a registered plan: 17,586 on 03/07/2024 and 3,000 on 03/07/2023, each for services rendered. Shares outstanding were 53,798,934; this is a baseline figure, not the amount being offered.
IMAX reported a Form 144 notice for a proposed sale of 49,504 common shares through Morgan Stanley Smith Barney LLC. The filing lists an aggregate market value of $1,743,926.91 and an approximate sale date of 11/10/2025 on the NYSE. The shares were acquired on 11/10/2025 via the exercise of options under a registered plan, with payment in cash. As context, 53,798,934 shares were outstanding.
IMAX filed a Form 144 notice for a planned sale of 6,188 common shares. The filing lists Morgan Stanley Smith Barney as broker, an aggregate market value of $211,909.30, and an approximate sale date of 11/10/2025 on the NYSE.
The shares were acquired on 11/10/2025 through the exercise of options under a registered plan, with payment in cash. Shares outstanding were 53,798,934. The signer represents they do not know of undisclosed material adverse information about the company.
IMAX Corp (IMAX): Form 4 insider activity. On 11/07/2025, Chief Legal Officer and Sr. EVP Robert D. Lister exercised stock options to acquire 50,143 common shares at $22.49 pursuant to a Rule 10b5-1 plan dated June 11, 2025, then sold 50,143 shares at $34.6652 the same day. After these transactions, he directly beneficially owned 161,421 common shares. The filing notes remaining restricted share units of 70,609. The options were issued in 2019 and set to expire on March 7, 2026, and the derivative balance following these transactions is listed as 0.
IMAX — Form 144 notice of proposed sale: A holder filed to sell up to 50,143 shares of Class A Common on or about 11/07/2025 through Merrill Lynch on the NYSE, reflecting an aggregate market value of 1,738,215.
The shares to be sold were acquired on 11/07/2025 via an exercise of options under a registered plan, paid in cash. Over the prior three months, the person reported selling 20,000 shares on 09/15/2025 for gross proceeds of 656,029. Shares outstanding were 53,798,934.